The realm of dermatology has been undergoing a profound transformation over the past decade, characterized by advancements in pharmacotherapies and an enhanced comprehension of disease pathophysiology, propelling the field forward at an accelerated pace. This progress is particularly evident in the management of psoriasis, where a proliferation of pharmacotherapy options has translated into tangible clinical benefits for patients.
For many years, topical steroids have been fundamental in treating plaque psoriasis and numerous other dermatologic conditions. However, their long-term use has been associated with increased tolerance and heightened risk of adverse events, necessitating the exploration of alternative treatment modalities. In May 2022, a significant milestone was reached with the FDA approval of tapinarof (Vtama), marking the introduction of the first nonsteroidal topical cream for plaque psoriasis. Shortly thereafter, in July 2022, roflumilast cream 0.3% (Zoryve) also received FDA approval, further expanding the therapeutic options available for this condition.
Backed by phase 3 clinical data demonstrating their efficacy and safety profiles in patients with plaque psoriasis, both tapinarof and roflumilast cream 0.3% hold promise in providing much-needed relief to affected individuals. However, the successful integration of these novel therapies into clinical practice necessitates overcoming significant challenges in terms of education and adoption.
To gain further insights into the evolving landscape of dermatologic care, particularly in the context of plaque psoriasis and the emergence of nonsteroidal topical treatments, HCPLive Dermatology’s editorial team engaged in a discussion with Dr. Mona Shahriari. Dr. Shahriari serves as an assistant clinical professor of dermatology at the Yale University School of Medicine and holds the position of associate director of clinical trials at Central Connecticut Dermatology Research.
Related Topics:
